{"url_path":"/sec/nmra/8-k/2026-06-15/item-2-05","section_key":"item-2-05","section_title":"Item 2.05 Costs Associated with Exit or Disposal Activities.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1885522/0001193125-26-270328-index.html","accession_number":"0001193125-26-270328","cik":"0001885522","ticker":"NMRA","issuer_name":"Neumora Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1885522/0001193125-26-270328-index.html","primary_entity_key":"0001885522","primary_entity_name":"Neumora Therapeutics, Inc."},"word_count":84,"has_tables":true,"body_markdown":"Item 2.05.\n\nCosts Associated with Exit or Disposal Activities.\n\nOn June 12, 2026, in connection with the discontinuation of development of navacaprant described below, the Company implemented a reduction in force of approximately 35%, which it expects to complete in the second and third quarters of 2026. The Company expects the reduction in force to result in an annualized cost savings of approximately $10 million, partially offset by one-time restructuring costs of approximately $2 million to be incurred in the second quarter of 2026."}